Annual vascular and bleeding outcomes in East Asian poststenting patients with acute coronary syndrome: The BRIC-ACS II trial

D Li,Y Yu,Y Chen

DOI: https://doi.org/10.1093/cvr/cvae088.190

IF: 13.081

2024-05-31

Cardiovascular Research

Abstract:Funding Acknowledgements Type of funding sources: None. Main funding source(s): no Objective We aim to determine the incidence of events in the 'real-world' ACS Chinese patients over 1-year after PCI. Methods and Results From November 2017 till April 2020, we enrolled post-stenting ACS patients (n=5515) from 30 hospitals with the strict 1-year follow-up (n=5150). Only 153(3.0%) patients developed MACE (a composite of all-cause death, myocardial infarction, ischemic stroke, or urgent coronary revascularization). The cumulative incidence of annual bleeding (BARC≥2) was 5.8% (298/5150). The BARC≥2 bleeding was higher 298 (5.8%) and was not associated with worsened MACE (P =0.52). Patients treated with ticagrelor (n=1620, 6.0%) had a significantly increased risk of bleeding than those treated with clopidogrel (n=2331; 4.1%) (HR=1.486; 95% CI:1.12-1.97; P=0.006), but similar risk of vascular MACE (2.7% vs 2.8%; HR= 0.94; 95% CI:0.64-1.38; P=0.747).The factors independently associated with the comprehensive risk of BARC≥2 bleeding and MACE, including female gender, renal insufficiency, peptic ulcer, atrial fibrillation, continuous use of ticagrelor and non-continuous DAPT. The discrimination of the nomogram model was further tested by the ROC curve (AUC value:0.610 (95% CI, 0.577-0.642)). Conclusions The annual incidence of BARC≥2 bleeding in ACS patients treated with PCI in China was higher (5.8%) than MACE (3.0%). DAPT with ticagrelor increased the bleeding rates with no trend towards MACE reduction.

cardiac & cardiovascular systems

What problem does this paper attempt to address?

This paper aims to address the incidence of vascular and bleeding events within one year after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) in East Asia. Specifically, the objective of the study was to determine the incidences of major adverse cardiovascular events (MACE) and bleeding events within 1 year after PCI in Chinese ACS patients in the "real - world".

The research methods included recruiting 5,515 ACS patients who had undergone stent implantation from November 2017 to April 2020 in 30 hospitals, and conducting a strict 1 - year follow - up on 5,150 of these patients. The research results showed that:

- Only 153 (3.0%) patients had MACE, which was defined as all - cause death, myocardial infarction, ischemic stroke or emergency coronary revascularization.
- The cumulative incidence of annual bleeding events (BARC ≥2) was 5.8% (298/5,150).
- Patients treated with ticagrelor (n = 1,620, 6.0%) had a significantly higher bleeding risk than those treated with clopidogrel (n = 2,331; 4.1%) (HR = 1.486; 95% CI: 1.12 - 1.97; P = 0.006), but the risks of vascular MACE were similar in both groups (2.7% vs 2.8%; HR = 0.94; 95% CI: 0.64 - 1.38; P = 0.747).
- Factors independently associated with the combined risk of BARC ≥2 bleeding and MACE included female gender, renal insufficiency, peptic ulcer, atrial fibrillation, continuous use of ticagrelor, and non - continuous dual - antiplatelet therapy (DAPT).
- The discrimination ability of the nomogram model was tested by the ROC curve, and the AUC value was 0.610 (95% CI, 0.577 - 0.642).

The conclusion points out that among ACS patients who received PCI treatment in China, the incidence of annual BARC ≥2 bleeding (5.8%) was higher than that of MACE (3.0%). Using ticagrelor for DAPT increased the bleeding rate, but did not show a trend of reducing MACE.